Sumitomo Dainippon Pharma Co Ltd (JP:4506)
:4506
Want to see JP:4506 full AI Analyst Report?
4506 Stock Chart & Stats
¥1854.50
¥4.00(0.72%)
At close: 4:00 PM EST
¥1854.50
¥4.00(0.72%)
Day’s Range― - ―
52-Week Range¥877.00 - ¥3,288.00
Previous CloseN/A
Volume1.08M
Average Volume (3M)5.45M
Market Cap
¥610.31B
Enterprise Value¥900.94B
Total Cash (Recent Filing)¥44.31B
Total Debt (Recent Filing)¥217.19B
Price to Earnings (P/E)5.1
Beta1.28
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)268.99
Shares Outstanding449,204,560
10 Day Avg. Volume5,265,230
30 Day Avg. Volume5,454,233
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,500.00Price Target Upside-19.12% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)212.2
Revenue Forecast (FY)¥527.11B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe sharp profitability turnaround in 2026 indicates restored operating leverage and earnings power versus prior loss years. Sustained higher margins can generate durable internal funding for R&D, commercialization and strategic initiatives, improving long-term cash resilience.
Improved LeverageMaterial improvement in leverage during 2026 reduces solvency and refinancing risk and increases financial flexibility. A more manageable capital structure supports multi-year investment in pipeline and commercialization, enhancing resilience across industry cycles.
Stronger Cash GenerationSubstantially improved free cash flow and high conversion of earnings to cash enhance the company’s ability to fund R&D, sustain operations and pursue partnerships without constant external financing, supporting durable operational independence if maintained.
Bears Say
Revenue VolatilityLarge swings in top-line revenue across 2024–2026 undermine visibility into demand and product lifecycle health. Persistent revenue volatility complicates planning, weakens predictability of margins and cash flow, and raises execution risk for long-term R&D and commercialization plans.
Historic Balance-Sheet RiskPrior periods of very elevated leverage demonstrate the company’s vulnerability to shocks and limited buffer during downturns. Recurrence of high leverage would constrain strategic optionality, increase interest exposure and raise the cost of capital for multi-year projects.
Inconsistent Cash FlowIrregular cash generation and episodic large outflows reduce the reliability of internal funding for clinical programs and market expansion. This inconsistency heightens the risk of future financing needs and can force suboptimal timing for investment or asset sales.
Sumitomo Dainippon Pharma Co News
4506 FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was ¥877.00 and its highest was ¥3288.00 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is ¥610.31B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 52 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on May 13, 2026. The company reported -¥2.04 earnings per share for the quarter, beating the consensus estimate of -¥15.241 by ¥13.201.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Overvalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd pays a Semiannually dividend of ¥7 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of -¥2.04 in its last earnings report, beating expectations of -¥15.241. Following the earnings report the stock price went up 2.516%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in JP:4506
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
4506 Company Deck
4506 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.View all JP:4506 earnings summaries4506 Stock 12 Month Forecast
Average Price Target
¥1,500.00
▼(-19.12% Downside)
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---